18561468. Volumetric Next-Generation in Situ Sequencer simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)
Contents
- 1 Volumetric Next-Generation in Situ Sequencer
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 Volumetric Next-Generation in Situ Sequencer - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Commercial Applications
- 1.9 Questions about Automated Volumetric Tissue Sequencing Device for Biomedical Research
- 1.10 Frequently Updated Research
- 1.11 Original Abstract Submitted
Volumetric Next-Generation in Situ Sequencer
Organization Name
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventor(s)
Karl A. Deisseroth of Stanford CA (US)
Ethan B. Richman of Palo Alto CA (US)
Volumetric Next-Generation in Situ Sequencer - A simplified explanation of the abstract
This abstract first appeared for US patent application 18561468 titled 'Volumetric Next-Generation in Situ Sequencer
Simplified Explanation
This patent application describes a sequencer for automated in situ sequencing of volumetric tissue samples, including a device capable of processing multiple samples simultaneously.
- The patent application introduces an automated sequencer for in situ sequencing of tissue samples.
- The sequencer can handle volumetric samples and operate on multiple samples at once.
- Methods for fabricating and using the sequencer are also included in the patent application.
Potential Applications
The technology described in this patent application could have various applications in the fields of medical research, pathology, and drug development.
Problems Solved
This technology addresses the need for automated and efficient sequencing of volumetric tissue samples, streamlining the process and increasing throughput.
Benefits
The benefits of this technology include faster and more accurate sequencing of tissue samples, which can lead to improved understanding of biological processes and disease mechanisms.
Commercial Applications
Title: Automated Volumetric Tissue Sequencing Device for Biomedical Research This technology could be commercially used in research laboratories, pharmaceutical companies, and diagnostic centers to enhance their sequencing capabilities and accelerate discoveries in the biomedical field.
Questions about Automated Volumetric Tissue Sequencing Device for Biomedical Research
1. How does this technology improve the efficiency of tissue sample sequencing? 2. What are the potential implications of using this automated sequencer in drug development research?
Frequently Updated Research
Stay updated on the latest advancements in automated sequencing technologies and their applications in biomedical research to further enhance the understanding and utilization of this innovative technology.
Original Abstract Submitted
A sequencer for automated in situ sequencing of volumetric tissue samples is provided. In particular, an automated volumetric in situ sequencing device capable of operating on multiple samples in parallel is provided. Methods of fabrication and use of the sequencer are also provided.
